SPINK5

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Thursday, February 10, 2022
NASDAQ, Private Securities Litigation Reform Act, Mutation, GLOBE, Forward-looking statement, Growth, CEE, Allergy, Netherton syndrome, Lists of diseases, Company, Infection, Asthma, Dermatitis, Patient, Intermediary, SEC, Epidermolysis bullosa, Biotechnology, Peeling skin syndrome, CIS, SPINK5, Partnership, Dehydration, Risk, Pharmaceutical industry, Ichthyosis, Mediterranean Sea

ASHBURN, Va., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.

Key Points: 
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, This is Quoins fifth distribution agreement for QRX003 since we went public four months ago.
  • The agreement with ER-Kim covers a number of important countries for rare and orphan diseases in Central and Eastern Europe.
  • Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.
  • Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Wednesday, January 26, 2022
Risk, SPINK5, Growth, Lists of diseases, Infection, Partnership, Forward-looking statement, Asthma, CIS, SEC, Dehydration, Private Securities Litigation Reform Act, NASDAQ, Netherton syndrome, Disease, Company, Peeling skin syndrome, Patient, Dermatitis, Mutation, Epidermolysis bullosa, GLOBE, Allergy, Pharmaceutical industry, Vaccine, Ichthyosis, Biotechnology

ASHBURN, Va., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with OrphanDC, a partner for biotech companies in Latin America, for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.

Key Points: 
  • Under the terms of the agreement, OrphanDC gains exclusive rights to commercialize QRX003 in Brazil, Argentina, and Colombia under a revenue sharing partnership.
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, Were excited to announce Quoins fourth distribution agreement for QRX003.
  • This agreement with OrphanDC covers Brazil, Argentina, and Colombia, which are the key markets in Latin America for rare and orphan diseases.
  • OrphanDC has a tremendous track record of delivering orphan drugs to rare disease patients, and we look forward to working with them to bring relief to patients suffering with Netherton Syndrome.

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome

Retrieved on: 
Wednesday, December 15, 2021
CEE, Forward-looking statement, Dehydration, CIS, Epidermolysis bullosa, Company, Lists of diseases, Dermatitis, Growth, Private Securities Litigation Reform Act, Netherton syndrome, WODA, Allergy, NASDAQ, Dermatology, Degenerative disease, SEC, Intermediary, CEO, Patient, Therapy, Evidence-based medicine, SPINK5, Mutation, Risk, GLOBE, Peeling skin syndrome, Infection, Partnership, Asthma, Compliance, Pharmaceutical industry, Netherton, Ichthyosis

Under the terms of the agreement, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS, and Quoin is obligated to supply the product to Orpharm, upon the receipt of regulatory approval.

Key Points: 
  • Under the terms of the agreement, Orpharm gains exclusive rights to commercialize QRX003 in Russia and CIS, and Quoin is obligated to supply the product to Orpharm, upon the receipt of regulatory approval.
  • QRX003 will be a much needed solution to patients suffering from Netherton syndrome in our region.
  • We are committed to supporting Quoin and leveraging our relationships with dermatologists and the broader rare disease community, states Pavel Shestiperov, M.D., CEO of Orpharm.
  • Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.

Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin’s Lead Asset, QRX003

Retrieved on: 
Thursday, November 11, 2021
Dehydration, Private Securities Litigation Reform Act, Netherton syndrome, Degenerative disease, NASDAQ, Project, Disease, Distribution, Peeling skin syndrome, Growth, Mutation, Forward-looking statement, MENA, SPINK5, Risk, Epidermolysis bullosa, Patient, Company, GLOBE, Solution, Therapy, Infection, SEC, Lists of diseases, Allergy, Specialty, Asthma, Dermatitis, Pharmaceutical industry

Under the terms of the agreement, Genpharm Services has exclusive rights to commercialize QRX003 in the Middle East and North Africa region, upon the receipt of regulatory approvals in both territories.

Key Points: 
  • Under the terms of the agreement, Genpharm Services has exclusive rights to commercialize QRX003 in the Middle East and North Africa region, upon the receipt of regulatory approvals in both territories.
  • Upon approval and launch of the product, Quoin will be entitled to a revenue sharing arrangement on net sales of the product.
  • The companies have also entered into an exclusive Supply Agreement, under which Quoin is obligated to manufacture and supply the product to Genpharm Services.
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, The licensing agreement with Genpharm is the second licensing agreement that weve announced for QRX003, which we are developing as a potential treatment for Netherton Syndrome.

Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003

Retrieved on: 
Monday, November 8, 2021
Dehydration, Private Securities Litigation Reform Act, Netherton syndrome, AFT, NASDAQ, Project, Distribution, Peeling skin syndrome, Growth, Mutation, Forward-looking statement, SPINK5, Risk, Epidermolysis bullosa, Sale, Patient, Company, GLOBE, Infection, SEC, Lists of diseases, Allergy, Asthma, Dermatitis, OTC, Pharmaceutical industry

ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into an exclusive License and Distribution Agreement with AFT Pharmaceuticals Ltd. (“AFT”) for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease.

Key Points: 
  • Under the terms of the agreement, AFT has exclusive rights to commercialize QRX003 in Australia and New Zealand, upon the receipt of regulatory approvals in both territories.
  • The companies have also entered into an exclusive Supply Agreement, under which Quoin is obligated to manufacture and supply the product to AFT.
  • Dr. Michael Myers, Chief Executive Officer of Quoin, commented, The licensing agreement with AFT is the first licensing agreement for QRX003, which we are developing as a potential treatment for Netherton Syndrome.
  • AFT is excited to work with Quoin Pharma to make this important treatment available to patients in Australia and New Zealand.